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Abstract
Cisplatin is a highly effective chemotherapy medicine used in the treatment of 
many childhood cancers. Like all medications, cisplatin has many side effects and 
as always the treatment of cancer in children is a balance between the risks of the 
medications used and their potential benefits. While many side effects of cisplatin 
chemotherapy are reversible, one major side effect is permanent and irreversible 
hearing loss (ototoxicity) in both ears which may worsen with time. The severity of 
cisplatin-related ototoxicity is associated with age and the cumulative dose received: 
the younger the child and the higher the total dose, the more severe the hearing 
loss may be. The spectrum of hearing loss varies from mild to moderate high tone 
hearing loss, to profound loss across the hearing range and permanent deafness. In 
addition to hearing loss, some children, especially adolescents, also experience tin-
nitus and vertigo. Cisplatin ototoxicity is one of most important of the many long-
term effects experienced by children who are cured of their cancer. The burden of 
this toxicity may be compounded by other long-term health issues that emerge with 
time. This chapter will focus on cisplatin-induced hearing loss, its mechanisms, its 
health impact on the young person and ways to mitigate or reduce the severity of 
ototoxicity. This chapter has been written by a multi-disciplinary team including 
paediatric oncologists, audiologists, a psychologist, a health scientist and a parent of 
a child growing up with high frequency hearing loss.
Keywords: cisplatin, chemotherapy, cancer, children, ototoxicity, hearing loss, 
tinnitus, vertigo, prevention
1. Introduction
Cisplatin is a chemotherapy medicine which can cause hearing loss, tinnitus and 
vertigo. The most common and well documented toxicity affecting the ear is hearing 
loss and will be the main focus of this chapter [1, 2].
1.1 Cisplatin
Cisplatin was first successfully used in the late 1970s as chemotherapy, in addi-
tion to surgery, for the treatment of men with testicular cancer and published in 
a landmark study in 1980 [3]. At that time Dr. Jon Pritchard at the Great Ormond 
Street Hospital for Children (GOSH) in London was researching new treatments for 
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childhood cancer and had a particular patient with widespread ovarian cancer who 
would previously have been moved to palliative care. However, seeing the effect of 
cisplatin on testicular cancer in young men, he thought it might work on ovarian 
cancer in young women and got urgent permission to treat his patient with this new 
medication. The child’s tumour had a spectacular response and shrank enough for 
the surgeon, at the time Professor Spitz, to successfully remove the tumour without 
having to perform a hysterectomy. She was cured and when she had children of 
her own, Jon became Godfather to her first child. The History of cisplatin and its 
introduction to medicine was captured by The Wellcome Trust in 2006 [4].
However, the challenge of introducing this powerful new chemotherapy to treat 
children with cancer was its toxicity, it was extremely emetogenic provoking severe 
nausea and vomiting, and was toxic to the kidneys (renal toxicity), ears (ototoxic-
ity) and peripheral nervous system (neurotoxicity). Research into the side effects 
of this medicine on children at GOSH began in 1985 when Dimitrios Kouliouskas 
started studying the renal toxicity [5, 6].
In 1987, both in Brussels and London, a combination treatment of cisPLAtin 
and DOxorubicin was showing promise in the treatment of children with large 
liver tumours (hepatoblastoma). These tumours need expert surgery to remove the 
whole tumour intact; this combination was able to shrink hepatoblastomas to make 
surgery safer and in some cases make it possible to remove previously unresectable 
tumours. It was Jon Pritchard who coined the phrase “PLADO” for this combina-
tion treatment when passing a Play-Doh store on the way back to the airport in 
Brussels. Later that same year at the annual meeting of the International Society 
of Paediatric Oncology (SIOP) in Jerusalem Jon, along with Dr. Jacques Plaschkes 
(Paedaitric Surgeon, Berne), Dr. Giorgio Perilongo (Padua) and others formed 
the International Society of Paediatric Oncology Epithelial Liver group SIOPEL to 
improve the treatment of children with liver cancer.
With increased use of cisplatin an alarming incidence of hearing loss was 
observed and at GOSH, Consultant Audiologist Sue Bellman noted a striking pat-
tern seen on hearing tests (audiograms). Audiograms are a measure of the intensity 
of sound in decibels (dB) required for a person to hear a particular frequency mea-
sured in Hertz (Hz). The patterns seen in children with cisplatin-related hearing 
loss were very consistent and led to the development of an ototoxicity grading scale 
(the Brock Grading Scale) which could be used to evaluate the hearing loss acquired 
by one child and compare it to that of other children treated with cisplatin [7]. In 
this way different treatment regimens of cisplatin could be compared for ototoxic-
ity. The grading scale showed that some children were more susceptible to cisplatin 
ototoxicity compared to others when given the same cumulative dose. This idiosyn-
cratic and varied severity suggests possible biological or genetic susceptibility to 
hearing loss and has led to years of study of the genetic predisposition of patients 
towards cisplatin ototoxicity.
Cisplatin remains one of the most effective chemotherapy drugs for childhood 
cancer and is a key component in the treatment of solid tumours, specifically, 
malignant germ cell tumours, liver tumours, neuroblastoma, osteosarcoma and 
retinoblastoma, but also brain tumours, particularly medulloblastoma and ependy-
moma. However, the occurrence of irreversible hearing loss that occurs in approxi-
mately 50% of cisplatin-treated children, is a serious clinical challenge [8–10].
The impact of the hearing loss, tinnitus and potentially vertigo caused by cispla-
tin has serious consequences for the child, their family and the society in which they 
live [11]. Very young children with even mild forms of hearing loss have difficulty 
developing the skills of language leading to communication problems and reduced 
school performance [1]. Acquired hearing loss in adolescents with previously 
normal hearing, causes serious social and emotional difficulties [12].
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In children with brain tumours, cisplatin-related ototoxicity is made more 
debilitating by damage to the hearing from surgery and radiotherapy, and ototoxic-
ity may compound the learning difficulties caused by radiation to the whole brain.
Other platinum based medications have been developed, (carboplatin and 
oxaliplatin), with the aim of reducing toxicity but they do not have the efficacy 
in many cancers to replace cisplatin except in certain circumstances. Carboplatin, 
which is now widely used in childhood cancer, is less ototoxic (its main toxicity is 
to bone marrow), but it cannot be substituted for cisplatin without careful clini-
cal trial evidence that it is as effective. When used in combination with cisplatin, 
the combined ototoxicity is greater than the sum of the two individual drugs [13]. 
When carboplatin is used at high dose, such as for bone marrow ablation prior to 
autologous bone marrow transplantation, it is ototoxic.
As it is unlikely cisplatin will be replaced by other agents to treat childhood can-
cer any time soon, monitoring its impact on a child’s development and education, 
increasing awareness of its effects and support for families, and finding ways to 
prevent ototoxicity are the key medical needs for the foreseeable future. The results 
of recent oto-protection clinical trials testing agents to mitigate cisplatin hearing 
loss have recently been assessed and a clinical guideline published [14, 15].
1.2 Hearing and balance
Hearing and balance are the two senses that are perceived by means of the inner 
ear that consists of the cochlea (the organ of hearing) and the vestibular system 
(the organ of balance), see Figure 1.
Hearing is the perception of sound and the vestibular system detects motion of 
the head and body. Together with vision and propriosepsis, which is the internal 
sense of positioning within the body, these senses are elementary for orienta-
tion and sense of safety in the world. For the developing child, normal hearing is 
essential to learn to detect, discriminate and identify sounds, culminating in the 
ability to use and understand spoken language, enjoy music and identify potential 
harm. A normal function of the vestibular system is essential for learning to move 
freely and efficiently. The importance of hearing for the development of speech 
Figure 1. 
The ear.
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and spoken language is well recognised and in several countries national newborn 
hearing screening programs have been implemented to detect congenital hearing 
loss as early as possible, and enable timely intervention. Hearing loss has many 
impacts on daily auditory functioning, communication, psychosocial wellbeing, 
and general health, so high quality hearing care for children is best delivered by 
multidisciplinary teams consisting of medical specialists, audiologists, speech 
language therapists and (developmental) psychologists. Acquired hearing loss may 
have multiple causes, but one of the most common causes in childhood follows 
treatment for childhood cancer with cisplatin.
For a sound to be perceived, it has to travel through the external ear, the middle 
ear, the cochlea and the auditory nervous system to the auditory cortex in the brain. 
Sound waves are collected by the pinna and channelled by the external auditory 
canal to the tympanic membrane, causing it to vibrate. The middle ear is an air-
filled cavity containing the ossicles (malleus, incus and stapes). The footplate of the 
malleus rests on the eardrum (tympanic membrane). When the membrane vibrates 
in response to sound it causes movement of the malleus. This movement is, in turn, 
transmitted via the incus and the stapes to the fluid filled cochlea.
The normal cochlea is a coiled structure with two and a half turns. It is divided 
lengthways into three fluid-filled compartments by two membranes (the basilar 
Reissner’s membrane). These create three fluid filled spaces, the scala tympani is the 
lower compartment, the cochlear duct (scala media) the middle one and the scala 
vestibuli the upper compartment. The inner ear hearing apparatus (the organ of 
Corti) consists of two types of sensory hair cells, the inner hair cells and the outer 
hair cells, resting on the basilar membrane.
When the middle ear stapes footplate moves, pressure waves in the cochlear 
fluid produce movement of the basilar membrane and the inner and outer hair cells 
in the organ of Corti. Excitation on the surface of the hair cells creates a neu-
rotransmitter impulse which is transmitted along the cochlear nerve (VIIIth cranial 
nerve) to the brain stem and auditory region of the brain. Damage to the inner hair 
cells from cisplatin, causes loss of this signal transmission, with the highest sound 
frequencies lost first.
2. Cisplatin and cisplatin-related toxicity
Childhood cancer is divided into haematological cancer and solid tumours. 
Haematological cancers occur in the bone marrow and lymph glands (leukaemia 
and lymphoma) and solid tumours occur in organs such as the liver, kidneys and 
nerves; solid tissues such as bone and muscle; and the brain (brain and spinal 
tumours). Cisplatin is currently used alone or in combination with other chemo-
therapy to treat solid tumours and brain tumours, and only rarely for leukaemia or 
lymphoma.
When given to children intravenously cisplatin causes acute nausea and 
vomiting, and may cause renal impairment (nephrotoxicity), neurotoxicity and 
ototoxicity. When given to adult patients, the dose limiting toxicity is neurological 
(peripheral neuropathy, tinnitus and vertigo) whereas in children its major long-
term effect is ototoxicity with permanent irreversible hearing loss. The severity 
of ototoxicity varies with age being more severe in younger children, the dose of 
cisplatin administered at each treatment and cumulative dose of cisplatin given 
during the course of treatment. However, susceptibility to these effects and their 
severity vary from individual to individual. Some children will develop very little 
toxicity despite large cumulative doses and others will develop relatively severe tox-
icity with only one or a few doses. The significant heterogeneity in the occurrence 
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of ototoxicity among similarly treated patients, suggests that genetic susceptibility 
contributes to the occurrence of cisplatin-related hearing loss in individual children 
[16–19] (section 2.5.3).
2.1 Cisplatin mechanism of action
Cisplatin is a simple chemical compound made up of an atom of the platinum 
metal bound with two atoms of chlorine on one side (cis) and two molecules of 
ammonia on the other side. When in solution in the blood surrounded by a high 
concentration of chloride ions cisplatin remains in its neutral form. However, 
when cisplatin enters a normal cell or a cancer cell which has lower concentra-
tions of chloride ions, cisplatin undergoes spontaneous hydrolysis with water. 
In this activated state it can enter the nucleus of a cell and become irreversibly 
bound into the double strands of nuclear DNA forming a cisplatin-DNA adduct 
(Figure 2).
Both normal and cancer cells have complex molecular mechanisms that have 
evolved to repair the damage to DNA caused by toxins such as cisplatin and other 
chemotherapy agents. If a cell can activate its molecular repair mechanism and 
successfully repair the damaged DNA, it will survive and continue to thrive, but if 
the damage is irreparable, both normal and cancer cells can switch on a molecular 
process called programmed cell death (apoptosis) and the affected cell will die. 
Cells can also resist the effect of cisplatin by producing free radicle oxygen mol-
ecules within the cell cytoplasm that neutralise the cisplatin molecule. The use of 
cisplatin in the treatment of children with cancer relies on the fact that solid tumour 
cancer cells are less able to repair DNA damage than normal cells, and are less 
resistant to cisplatin, making them more susceptible to apoptosis than the child’s 
normal tissues. However, within the cells of some normal tissues such as within the 
hearing apparatus, the kidney and peripheral nerves are directly damaged by the 
effects of cisplatin.
Figure 2. 
Cross section of the cochlear scalae in the basal turn.
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2.2 Cisplatin administration
Cisplatin can only be administered intravenously. It is infused via a central 
venous catheter over various times but usually between 1 and 6 hours, and 
given with a large amount of hydration fluid with a high chloride concentra-
tion to reduce its toxicity. The hydration is usually administered over 24 hours 
so the child must stay in hospital during its administration. If the child is not 
hospitalised throughout this time, adequate hydration needs to be managed by 
other means.
In the early years, cisplatin was administered for an hour following a period of 
hydration of about 6 hours, with another 24 hours hydration afterwards.
Times of administration of cisplatin began to lengthen in the late 1980’s when 
it was found that lengthening the infusion time reduced the severity of the nausea 
and vomiting the child experienced. Cisplatin infusion times in Europe reached 
up to 96 hours continuous infusion. However, with the introduction new classes of 
antiemetic drugs in the 1990’s, specifically the HT3 inhibitors (ondansetron and 
others) the cisplatin infusion times were able to be reduced [20].
In some settings and for some cancers, the dose of cisplatin was split over 5 days 
reducing the need for 24-hour hydration and hospitalisation. So, in place of a stan-
dard dose, and very emetogenic, dose of 100 mg/m2 on one day, 20 mg/m2 would be 
given on day 1 through 5.
2.3 Cisplatin and emesis
Cisplatin is highly emetogenic. The nausea and vomiting which ensues appears 
to be universal. Fortunately, the introduction of the HT3 inhibitors in the 1990s 
and additional classes of antiemetics more recently, the severity of emesis can be 
greatly modified in most children [20]. However, effective antiemesis requires 
a cocktail of antiemetics to be given at least 30 minutes prior to administering 
cisplatin and that the best antiemetic control is achieved from the very first cis-
platin dose. Inadequate antiemetic treatment at the start of cisplatin therapy can 
lead to the development of anticipatory vomiting which is a particular problem 
in adolescents. This is when a patient starts to vomit when the idea of receiving 
chemotherapy is triggered for example on sight of the hospital or if they meet a 
ward staff member in a shop. Once anticipatory vomiting has become established it 
is very difficult to control.
2.4 Cisplatin nephrotoxicity
Cisplatin is almost entirely excreted through the kidney. When in its ionised 
form, cisplatin is very toxic to kidneys, so to ensure cisplatin is excreted in non-
ionised form it needs a high concentration of chloride ions in the posthydration 
fluid. Nephrotoxicity in young children is partially reversible although this may be 
due to further maturation of the kidney in very young children rather than actual 
improvement [5, 6].
2.5 Cisplatin ototoxicity
The hearing loss caused by cisplatin is permanent and bilateral and it may 
worsen with time. It is worse in very young children, the ear at this age appears 
to be more susceptible to damage compared to that in older children and adults. 
Cisplatin causes high frequency hearing loss which may happen following the first 
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cycle of treatment and once acquired it tends to worsen with increasing cumulative 
doses of cisplatin and eventually may spread towards the lower frequencies impor-
tant for speech [7].
2.5.1 How cisplatin enters the ear
Cisplatin enters the inner ear or cochlea through a number of molecular 
transport pathways as shown in Figure 3 [21]. The cochlea (and vestibulum) is 
surrounded by several distinct barriers separating the inner ear vasculature and the 
inner ear fluid compartments that are filled with perilymph, endolymph or intra-
strial fluid. Their anatomical sites are not yet clearly identified, but Neiberg et al. 
[22] summarise them as follows: “tightly coupled vascular endothelial cells form the 
blood-perilymph or blood-labyrinth barrier (BLB)”. The same authors consider the 
separation between blood, endolymph and intrastrial fluid as being more complex: 
“tightly coupled strial endothelial cells form the barrier between blood and intra-
strial fluid”. This latter is separated from endolymph by epithelial marginal cells in 
conjunction with endothelial basal cells from the intrastrial compartment. These 
are also referred to as the blood-strial barrier or intrastrial fluid-blood barrier. The 
more general use of the term BLB covers all of these barriers.
The BLB plays an important role in cochlear homeostasis to maintain its func-
tional integrity. As a highly specialised capillary network it selectively allows the 
passage of nutrients and ions in and out of the cochlea, and functions as a shield 
to protect the inner ear from toxic agents. However, cisplatin seems to affect the 
stria vascularis and might cause breakdown of the BLB [23]. The permeability 
of the BLB is also influenced by inflammation, diuretics, noise and a number of 
other factors [22]. Several organs including the liver, spleen and kidneys are able 
to rapidly clear cisplatin and its derivatives. Due to its unique structure, however, 
this ability is considered to be low for the cochlea [24]. Thus, the BLB may serve 
as a port of entry for cisplatin, from which it is hard to escape. Cisplatin may be 
retained in the cochlea for several months to years after treatment [24]. Another 
drawback of the BLB that is mentioned in [22] is the difficulty it poses to deliver 
otoprotective agents to the cochlea as systemic delivery is highly inefficient 
while local delivery is inherently invasive with limited permeability of the round 
window membrane.
Figure 3. 
Cisplatin structure and mechanism of action [20].
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2.5.2 Destruction of the hair cells of the cochlea
Cisplatin causes irreversible damage to the outer hair cells of the cochlear 
apparatus located in the inner ear. Once within the perilymph cisplatin may remain 
permanently trapped in the inner ear and may continue to cause delayed hearing 
loss [24]. The molecular mechanism of cisplatin related ototoxicity and destruction 
of the outer hair cells is currently unknown. It is thought to involve the production 
and activation of Reactive Oxygen Species, (ROS), within the cell cytoplasm which 
the cell attempts to neutralise by a specific molecular mechanism. However, the 
capacity of the inner hair cells to neutralise ROS may become exhausted with time 
or exceeded by the cisplatin dose, leading to inner hair cell death. Inner hair cells 
in the cochlea are fixed in number and do not regrow, so once destroyed hearing 
begins to be lost. This would explain why higher doses of cisplatin given per day 
cause more toxicity. Figure 4 shows how the hydrated complex is neutralised by 
the cell [25].
2.5.3 Genetic susceptibility to hearing impairment
Over the years, several studies have focused on genetic susceptibility to 
cisplatin-induced hearing loss using candidate single nucleotide polymorphism 
(SNP) approaches and more recently genome wide association studies (GWAS). 
Results to date are conflicting, as studies were often underpowered and did not 
included multiple testing or replication efforts. Differences in patient populations 
(e.g., ancestry), sample size, methods of audiometric testing and end point defini-
tions with regards to audiological testing or classification attributable factors that 
may explain these discrepancies in results and have shown, that certain cohort and 
Figure 4. 
Model of the cochlea and cisplatin (Pt) trafficking routes. Potential pathways for systemic Pt to cross the 
blood-labyrinth barrier and enter hair cells include (1) a transstrial trafficking route from strial capillaries to 
marginal cells, followed by clearance into endolymph; (2,3) traversing the blood lymph barrier into perilymph 
and subsequently into endolymph via transcytosis across the epithelial perilymph/endolymph barrier. (4) once 
in endolymph, Pt enters haircells across their apical membranes. (5) Pt in the scala tympani could also pass 
through the basilar membrane into extra cellular fluids within the organ of Corti and enter haircells across 
their basolateral membranes. S stria vascularis; F spirocytes in spiral ligament [22].
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treatment factors (e.g. cranial irradiation, type of platinum agent, total cumulative 
doses and use of co-medication) may be even more important than genetic suscep-
tibility. In addition, comparison of genetic studies to date have been hampered by 
heterogeneity in phenotype definitions Table 1 [26–28].
Currently, efforts are being made to identify and meta-analyse relevant genetic 
variants, to enable the selection of children with a high risk of platinum related 
hearing loss to facilitate clinical decision making and where possible to intervene 
to prevent ototoxic damage. Alongside intensifying hearing screening any other 
intervention would require careful clinical risk assessment aided by thoughtful 
discussions with parents, carers and older children themselves. This could then lead 
to agreeing on an alternative cancer treatment plan for the child [29].
2.5.4 Hearing assessment in children
Functional hearing is represented by ‘air conduction’ thresholds measured 
using headphones, and ‘bone conduction’ thresholds measured using a vibrator 
placed on the mastoid bone. The air conduction thresholds indicate the status of 
the external ear, middle ear, cochlea and central auditory nervous system. The bone 
conduction thresholds indicate the status of only the cochlea and central auditory 
nervous system.
2.5.4.1 Testing of the status of the external and middle ear
A check-up of external - and middle ear status is required to exclude any 
conditions causing obstruction for the sound to reach the cochlea. When sound is 
obstructed from reaching the cochlea, this is called a conductive hearing loss. Causes 
for conductive hearing loss include accumulation of cerumen, infections or tympanic 
membrane perforation [30]. Otoscopy allows for visual inspection of the auditory 
canal, the tympanic membrane and part of the middle ear. Tympanometry may be 
used to indicate the presence of middle ear pathology, by measuring the mechano-
acoustic properties of the middle ear system [31]. A probe is placed in the ear canal 
for a few seconds, which delivers a tone and changes the air pressure. The way in 
which the pressure changes affect the sound level developed in the ear canal can 
provide useful information about the status of the middle ear.
2.5.4.2 Behavioural testing of inner ear status
Several behavioural tests are available to estimate hearing thresholds in children. 
The reliability of these tests depends on the child’s age, neurological status, develop-
ment and motivation.
The usual way to assess hearing function in older children and adults is to mea-
sure the air and bone conduction thresholds, i.e. the quietest sounds which can be 
detected, as most hearing problems are associated with raised (poorer) thresholds. 
Audiometry is the process of measuring hearing thresholds at a range of frequencies 
(pitches). Thresholds may be measured in various ways and are usually displayed on 
an audiogram, which shows the thresholds at each audiometric frequency. Different 
types of hearing loss and their classifications can be found in a previous IntechOpen 
book [32]. Figure 5 shows a typical Pure Tone Audiogram of normal hearing on the 
left and moderate cisplatin induced high frequency sensorineural hearing loss on 
the right.
The horizontal axis shows the test frequencies. Octave intervals are tested from 
125 or 250 to 8000 Hz (8 kHz). The vertical axis is the level of sound in decibels 
- termed dB HL (Hearing Level) where the quietest levels are at the top. Thus, 
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the “normal range” is anything down to 20 dB HL (vertical axis) and thresholds 
higher than 20 dB HL (lower on the audiogram) represent a clinically signifi-
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but no replication
GJB2 rs80338939 9 Yes
but no replication
GSTP1 rs1695 5,12,15# CR






















Yes GWAS n = 511 replication in 18.620 
subjects
testicular cancers
No CGA in 900
ped cancer patients
*SNPS that were tested once, but not found to be associated with ototoxicity were not included. CR = conflicting result 
CDA = candidate gene approach. #: studies that adjusted for multiple testing.
(1)Thiesen, Pharmacogenetics and genomics, 2017; (2)Vos,Ppharmacogenetics and genomics, 2016; (3)Hagleitner, 
PloSone, 2014; (4)Yang, Clinical Pharmacology and Therapeutics, 2013; (5)Rednam, 2013; (6)Pusegoda, Clinical 
Pharmacology and Therapeutics 2013; (7)Choeypasert,2013;, (8)Riedeman, 2008; (9)Knoll, Laryngoscope, 2006; 
(10)Peters, AntiCancer drugs, 2000; (11)Brown,Cancer Med, 2015; (12)Ross, Nat Gen, 2009; (13) Xu, Nat Gen, 
2015; (14) Wheeler, Clin Cancer Research, 2017; (15)Langer, EJC, 2020).
Table 1. 
Relevant SNP studies on cisplatin related hearing loss in childhood cancer by candidate gene studies*.
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conduction thresholds are more or less the same, but when there is a hearing loss the 
air conduction thresholds are depressed further.
Figure 6 shows the levels and conductive frequencies of a variety of environ-
mental sounds and components of speech (the so-called “speech banana”) in an 
audiogram format. Overlaying any audiogram onto this can indicate which sounds 
are audible and those which would be inaudible, which can illustrate the functional 
implications of various configurations of hearing loss.
For the results of audiometry to be reliable, the child has to understand the 
instructions and has to be motivated to comply. For children younger than 5 years of 
age, audiometry is generally too challenging. Therefore, several other behavioural 
tests are available to estimate hearing thresholds in children. The reliability of these 
tests depends on the child’s age, neurological status, development and motivation.
Visual reinforcement audiometry is applied to estimate hearing thresholds in 
young children (6 months to 3 years of age). A visual reinforcer, such as an ani-
mated toy or picture is used to generate and maintain a head turn response to the 
sound stimulus presented through a speaker or ear phones.
To measure hearing thresholds in children aged 3 to 5 years, conditioned play 
audiometry may be applied. The child is conditioned to respond to a sound by 
performing an action (putting blocks in a box or stacking rings on a stick) [30].
Figure 5. 
Cisplatin’s interaction with the cochlear antioxidant defence system. Cisplatin is converted to a  
cis-diammine(aqua)chloroplatinum(II) (a monohydrate cisplatin complex) upon entering the cell cytoplasm. 
These reactive platinum species can react with molecular oxygen (O2) to generate superoxide (O2
−−) which is 
detoxified by superoxide dismutase (SOD) to hydrogen peroxide (H2O2) and oxygen. Hydrogen peroxide is 
further detoxified by catalase to water (H2O) and oxygen. Cisplatin reactive intermediates readily bind to and 
oxidise the antioxidant reduced glutathione (GSH) to oxidised glutathione (GSSH). Glutathione peroxidase 
(GSH.Px) consumes GSH to produce glutathione disulfide (GSSG) in the process of converting H2O2 to 
H2O. Glutathione reductase (GR) reduces GSSR to GSH by using the reduced form of nicotinamide adenine 
dinucleotide phosphate (NADP+) NADPH, as cofactor [24].
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Conventional audiometry has been considered the gold standard for obtaining 
hearing thresholds between 0.125 to 8 kHz in children of 5 years and older. The 
child presses a button in response to the sound stimulus. Additionally, the extended 
high frequencies (EHF) up to 16 kHz may be tested for identification of early 
ototoxic damage. EHF testing is less widely applied as special calibration of the 
equipment is required (A.J.M. Meier et al. in press).
2.5.4.3 Objective testing of inner ear status
For infants up to 6 months of age, behavioural tests are too inaccurate for hear-
ing threshold estimation. To asses hearing of children of this age, objective tests are 
available and widely used in programs for new born hearing screening. These tests 
can also be used to confirm the outcome of behavioural testing in older children, 
and may be applied in children/adolescents who are not able to cooperate.
A simple and fast way to objectively assess hearing is a test of otoacoustic 
emissions (OAE), in which a soft probe is placed into the ear canal and the OAE or 
“cochlear echo” is recorded in response to moderate level clicks or a combination of 
pure tones delivered via the same probe. OAEs reflect the function of outer hair cells 
and are only produced in ears with normal hearing or a mild loss of 20–30 dB HL. 
Presence of an OAE response confirms normal or near-normal hearing. Absence of 
a response indicates the possibility of a hearing loss and the need for follow-up test-
ing, though it is often due to temporary factors such as excessive head movement or 
middle ear fluid.
The main follow-up test in this age group is auditory brainstem response (ABR) 
testing. Disposable electrodes are attached to the baby’s head and rapid clicks or 
tone pips are delivered to the ear by an insert probe. The electrodes detect field 
potentials generated by the lower auditory pathways (cochlea and brainstem), pro-
ducing a characteristic waveform response. The intensity of the stimuli is reduced 
until the waves are no longer visible, providing a close approximation to behavioural 
hearing thresholds. When the equipment is well calibrated and click stimuli are 
used, hearing thresholds around 3 kHz can be estimated, type of hearing loss can be 
determined (conductive or sensorineural) and integrity of the VIIIth cranial nerve 
and lower brainstem can be assessed. ABR is preferably measured during sleep, but 
in some situations sedation must be applied ([30], A.J.M. Meier et al. in press).
Figure 6. 
An audiogram with air conduction thresholds from a child with normal hearing on the right and moderate 
hearing loss on the left.
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2.5.5 Monitoring of ototoxicity in children
As cisplatin-induced ototoxicity in children may have a negative impact on 
speech-language development and quality of life, early detection of hearing loss by 
audiological assessments is important. Monitoring during and after cancer therapy 
facilitates audiological management including counselling of patients and fam-
ily, and support of hearing function if necessary (hearing aids, assistive listening 
devices, speech and language therapy) [33]. During therapy, monitoring may also 
provide the opportunity to modify cisplatin dose, depending highly on the avail-
ability of an evidence-based alternative, and whether or not cisplatin is the back-
bone of treatment. For example, dose adjustment is not applicable in patients with 
liver tumours, for whom cisplatin is the key component of survival [34].
2.5.5.1 Timing and frequency of testing
A baseline assessment before start of cisplatin treatment is important to identify 
pre-existing hearing loss, and is accompanied by questions on medical history 
including previous ear and hearing problems, family history, a check for dysmor-
phic features and presence of tinnitus. The timing of monitoring and the testing 
schedule during cancer therapy highly depends on the protocol and patient-specific 
circumstances. Serial assessments can be considered for patients who receive 
cisplatin, including a check of middle ear and inner ear function, and presence of 
tinnitus. A post-treatment assessment is used to identify hearing loss or to record 
progressive changes in hearing status, often performed within three months after 
cessation of treatment (A.J.M. Meier et al. in press). It may be necessary to continue 
monitoring up to several years after treatment to detect a delayed onset of hearing 
loss. Surveillance is advised annually for young survivors, every other year for older 
children, and every five years for adolescents and young adult survivors [35].
2.5.6 Grading of hearing loss in children
When cisplatin was first used in young children at GOSH there were no appro-
priate grading scales with which to compare ototoxicity measurements taken from 
children receiving the same or different treatments including cisplatin. There 
were the common toxicity criteria of adverse events (CTCAE) and the American 
Speech-Language Hearing Association (ASHA) criteria, but both compared hear-
ing measured after treatment to baseline hearing. These approaches can be used 
in older children where baseline hearing can be established. In very young sick 
children it is difficult to get a reliable baseline and the tests used at a very young 
age are not the same as the tests used later on. Sue Bellman, the audiologist at the 
time at GOSH studied the particular pattern of hearing loss which the children were 
developing. She designed a scale which was published by Brock in 1991 and became 
known as the Brock grading [7]. Brock grading was later thought not to be sensitive 
enough and was developed further and a new scale published by Kay Chang in 2010 
[36]. There followed a consensus meeting at the annual general meeting of SIOP in 
Boston and the SIOP scale was introduced and published in 2012 [21]. In Figure 5 
above the audiogram on the right which is normal would be graded as SIOP grade 0 
whereas the audiogram on the right would be graded as SIOP grade 2. Grading can 
be done from the audiogram locally but when comparison of grading is required 
for the purposes of studying the toxicity of one treatment regimen with another in 
a clinical trial then central review of audiograms is necessary to assure consistency 
and quality. This is particularly the case in international clinical trials where the 
audiogram needs to be uploaded to the trial database for review.
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2.5.7 The developmental and psychological impacts of hearing loss
The developmental and psychological impacts of deafness on children are diverse 
and substantial. In addition to the primary influence of hearing loss on the acquisition 
of language and literacy skills, children with any degree of hearing loss are at increased 
risk of experiencing social, emotional and behavioural difficulties as well as potential 
influences on quality of life, identity and self-esteem. All these consequences are well 
documented for children with congenital hearing loss, with research typically focusing 
on children with severe or profound deafness, and recently, those who have received 
cochlear implants. Research findings reveal a highly complex picture, with a large 
number of factors interacting to result in the difficulties presented by any individual 
child, including for example their language and communication skills, the cause of 
their deafness, their educational provision, and parental socio-economic status. The 
picture is somewhat less clear for children who have a mild or moderate hearing loss 
(often referred to as minimal hearing loss, and the largest group of children affected 
by ototoxicity), or those who acquired a loss during childhood due to illness directly 
(for example meningitis), or as in the case of ototoxicity, due to the treatment of 
illness. However, there is increasingly empirical evidence that is relevant in relation to 
the developmental and psychological impacts of ototoxicity-induced hearing loss.
The most significant impact of hearing loss is during infancy and early child-
hood, when language skills are developing at their fastest but delays may go unrec-
ognised or untreated until the child enters school [37]. Thus age of exposure to 
ototoxic drugs is of particular importance, since even if the hearing loss is confined 
to the high frequencies, it can have subtle but significant impacts on speech percep-
tion and therefore speech production and intelligibility [38, 39]. Audibility and 
recognition of high-frequency speech sounds (s, f, th, sh, h, k, and t) and percep-
tion of fricative phonemes (e. g./s/) supports phonological and morphological 
development in young children with normal hearing and children with hearing loss 
[39]. Delays in language development acquired at this time may be hard to reverse, 
even with appropriate amplification and speech therapy [40].
A review of the literature on minimal hearing loss (comprising 69 articles, 6 of 
which included children with high-frequency hearing loss) concluded that although 
some individuals appeared to have no observable speech-language or academic 
difficulties, others experience considerable problems [37]. Those children that per-
form in the normal, average range on tests of language skills and academic attain-
ments may in fact be under-performing in relation to their cognitive potential (IQ ). 
In addition, children who appear not to have been negatively affected in terms of 
language and academic development, may still present with significant psychoso-
cial problems. As a group, children with any degree of hearing loss, as well as those 
specifically with minimal hearing loss, exhibit higher rates of behaviour problems 
such as noncompliance, aggression, hyperactivity, impulsivity, and inattention than 
their hearing peers. They also have more emotional problems such as lower energy 
levels, higher stress and poorer self-esteem.
The psychosocial impact of hearing loss is also seen in terms of the effect on qual-
ity of life. A systematic review of 41 articles [41], showed that children with hearing 
loss generally report a lower quality of life than their normally-hearing peers. Their 
meta-analysis on four studies employing the Paediatric Quality of Life Inventory 
(PedsQL), revealed statistically and clinically significant differences in PedsQL scores 
between children with normal hearing and those with hearing loss, in the Social and 
School domains. Recently, a study reported detrimental effects of hearing loss on 
quality of life in children and adolescents who suffered hearing loss following oto-
toxic treatment compared with those whose hearing was unaffected [11]. All the areas 
assessed were impacted, including the ability to communicate with family and peers, 
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level of independence, interactions with peers and emotional well-being. Long-term 
follow-up of childhood cancer survivors indicates significant hearing loss as predic-
tive of poorer outcomes for school, employment and independent living [42].
As a result of these developmental and psychosocial consequences of ototoxic-
ity-induced hearing loss it is essential that children are not only closely monitored 
in terms of their hearing thresholds, but also the wider language, learning, social, 
emotional and behavioural impacts. A range of interventions may be needed, 
including speech and language therapy, classroom and teaching accommodations 
and strategies to maximise access to speech and peer interactions, as well as thera-
peutic interventions to address emotional and behavioural problems.
2.5.8 Resource challenged nations and cisplatin hearing loss
The Global Initiative for Childhood Cancer (GICC) which was launched in 2018 by 
the WHO in partnership the International Society of Paediatric Oncology has the goal 
of improving the Global survival of children with cancer to 60% by 2030. As child can-
cer services develop and more gain children access cancer care, it will be necessary to 
develop policy and services to address the long term effects of chance treatment [43]. 
Cisplatin, is included in the WHO Essential Medicines List for Children (2017), but 
severe acquired hearing loss in child cancer survivors may have very significant impact 
on learning and future education opportunities of survivors and increase the health 
burden in families [44, 45]. Studies from low-and middle-income countries report the 
prevalence of hearing loss in community screened children as about 10%, while it is 
23% for children with co-morbidities, such as HIV, tuberculosis, chronic suppurative 
otitis media and impacted cerumen% [46, 47]. Adding cisplatin as childhood cancer 
treatment may therefore increase the prevalence of hearing loss, which increases the 
need for early identification in the context of limited resources. Community health 
care workers have been successfully trained to assist and implement screening for 
hearing loss in communities, which should be used to assist in continuous assessment 
of hearing in children, surviving childhood cancer after cisplatin treatment and return 
to their communities [45]. These identified children should be referred back to the 
major urban treatment centres for further more sophisticated hearing assessment 
and management. However, it should be noted that in Sub-Saharan Africa, and of 
the most populous parts of South East Asia there is a general lack of audiologists and 
limited access to testing and hearing support, which may hamper rehabilitation. These 
resource-constricted countries should therefore establish partnerships with developed 
countries and non-governmental organisations to assist them in the management of 
childhood cancer survivors with hearing loss due to cisplatin [48].
2.5.9 The parent’s perspective
A parent with a child going through treatment is always trying to find the bal-
ance between a desperate longing for their child to be cancer free whilst enduring 
the least possible short and long-term side effects. At the start of treatment, when 
doctors explain the risks of potential hearing loss when using cisplatin, it can be 
hard to fully appreciate and understand the long-term impact for your child. At this 
stage of treatment many different outcomes are as yet unknown. This is especially 
true if the child receiving treatment is very young and unable to communicate 
verbally. The impact of having to wear hearing aids and other assistive listening 
devices is unknown and therefore almost impossible to comprehend. Whilst going 
through treatment the support given by doctors and nurses is invaluable. Once 
treatment ends access to that level of specialised support ends too. Parents are 
delighted to have a child free from cancer but all too often they are left to deal with 
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the consequences of long-term side effects on their own. This can mean that young 
children learning to speak, read and write are not given adequate learning support 
since parents do not always know how best to help them or even what kinds of basic 
learning support to ask for. At a young age the child will not know in what circum-
stances they find it difficult to hear and parents need to be aware of every situation 
in order to be able to help the child develop coping strategies. This is especially 
true in nursery and primary school settings where a child could quickly feel over-
whelmed. It would be easy for that child to be incorrectly labelled as reclusive, of 
low ability or naughty in class. As the child gets older, they will be able to deal with 
situations more easily themselves but will easily get tired and quickly zone out. 
Parents might need to advocate for their child and make the school aware of their 
needs. Interventions could include sitting at the front of exam halls, increasing 
teacher awareness in situations like sports pitches, playgrounds, swimming pools 
and in noisy classrooms. It is easy for a child with hearing loss to retreat from inter-
actions or to become frustrated and then behave poorly. Parents need assistance and 
information to know how best to help and support their child. Children need to be 
encouraged to ask for help rather than be singled out or stigmatised.
2.5.10 The search for otoprotectants
As soon as it was known that cisplatin caused irreversible hearing loss research-
ers began to look for drugs to protect against this side effect. Different medications 
have an impact at different points in the metabolism of the cell Figure 7 [49].
2.5.10.1 Preclinical studies of ototprotectants
The most promising pre-clinical studies have come from Edward Neuwelt’s team 
in Portland Oregon [50–52]. They have been working on Sodium Thiosulfate (STS) 
and N-Acetyl Cysteine (NAC). As can be seen in Figure 8 in the section above these 
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2.5.10.2 Clinical trials of otoprotectants in children
In 2019 a clinical guideline paper was written by a multidisciplinary team led by 
Lillian Sung and David Freyer [15]. The conclusion of this paper was that to date 
the most promising otoprotectant is STS, see Table 2 taken from this paper. STS is 
close to being licenced both in North America and Europe. The evidence for the use 
of STS in children comes from two phase III trials [53, 54] which both showed that 
the incidence of hearing loss can be reduced by 50% in children receiving STS as a 
15 minute infusion given 6 hours after the cisplatin infusion ends.
2.6 Cisplatin neurotoxicity
In adults, peripheral sensitive neurotoxicity which ranges from paresthesias 
to ataxic gait is the dose limiting toxicity of cisplatin [55]. This means that when 
patients develop severe neurotoxicity the dose of cisplatin needs to be adapted or 
stopped. In young children neurotoxicity is rarely observed.
2.7 Hearing conservation from the public health perspective
Cisplatin hearing loss is considered to worsen with time. It is not clear whether 
this is due to ongoing toxicity from platinum retained in the cochlea or the addition 
of further assaults on the ear or both. Hearing educational programs for the young 
Figure 8. 
General mechanistic pathways of cisplatin-induced cytotoxicity in auditory cells and the mechanistic pathways 
by which the otoprotective clinical candidates combat cisplatin toxicity [47]. https://doi.org/10.1021/acs.
jmedchem.7b01653.
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are few and far between [56]. It is clear that children who have received cisplatin as 
part of their therapy for cancer need to be supported but also educated as they go 
through follow up to conserve their hearing. It is possible that at the end of treatment 
ototoxicity damage is not yet apparent to the young person as it may only affect the 
higher frequencies out of their speech range. With time however as hearing worsens 
as a result of the toxicity, possibly in interaction with noise induced hearing loss 
[57], it may reach the speech frequencies and become apparent. Hearing conserva-
tion strategies should be introduced to the parents and child at an early stage and 
should encourage exclusion/reduction of factors which can lead to damage to 
residual hearing. Not all of these factors can be excluded however it is only fair that 
parents and patients are made aware of the additional risk to hearing that they bring. 
These include: loud sounds and noises; other ototoxic medication e.g., aminoglyco-
sides; unhealthy diets; intracranial pressure changes for example as can occur with 
certain sports such as scuba diving; barotrauma; head injury and exposure to radia-
tion and proton beam therapy. Where possible children and adolescents should be 
discouraged from listening to loud music through headphones over long periods of 
time, encouraged to wear protective ear plugs if exposed to loud noise, wear protec-
tive head gear when cycling; use a head rest/child safety car seat adjusted to height.
To raise awareness of policy makers to address the problems of preventable hear-
ing loss worldwide, the WHO World Health Assembly adopted a resolution in 2017 
Studies (n) Patients (n) Effect 
size *
95% CI I2 (%) Value
Amifostine vs no treatment
Any ototoxicity 5 465 RR 0.96 0.71 to 
1.29
49% 0.78
Severe ototoxicity 4 223 RR 0.85 0.34 to 
2.12
0% 0.72
Sodium diethyldithiocarbamate vs no treatment
Severe ototoxicity 2 255 RR 0.73 0.08 to 
6.44
56% 0.77
Sodium thiosulfate vs no treatment
Any ototoxicity 2 205 RR 0.51 0.37 to 
0.71
0% <0.0001
Intratympanic acetylcysteine vs no treatment
Threshold at 4 kHz 2 62 MD-2.7 −14.9 to 
9.5
0% 0.66
Threshold of 8 kHz 2 62 MD-1.6 −14.8 to 
11.6
0% 0.81
Intratympanic dexamethasone vs no treatment
Threshold at 4 kHz 2 92 MD-0.7 −5.8 to 
4.5
0% 0.80
Threshold at 8 kHz 2 92 MD-8.7 −18.1 to 
0.7
34% 0.07
Continuous cisplatin infusion vs bolus cisplatin infusion
Any ototoxicity 2 78 RR 1.60 0.62–
4.13
0% 0.33
RR = risk ratio MD = mean difference *RR less than 1 and MD less than 0 favour intervention.
Table 2. 
Data synthesis of trials for cisplatin-induced ototoxicity prevention.
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(WHA70.13) to provide guidance for member states for the integration of ear and 
hearing care into national health plans. In response The World Report on Hearing 
has been developed (https://www.who.int/activities/highlighting-priorities-for-
ear-and-hearing-care), proposing a set of interventions for prevention, screening, 
rehabilitation and communication.
2.8 Future challenges
A better understanding of the predisposing genetic factors and how to influence 
them as well as the introduction of licenced otoprotectants will hopefully reduce 
the incidence of acquired ototoxicity. In the meantime children who have already 
developed hearing loss or other ototoxicity need expert support, audiological inter-
vention as well as encouragement, acceptance, patience and tolerance to support 
them fully socially integrating.
3. Conclusion
Cisplatin ototoxicity is a serious medical problem in children with cancer whos’ 
cure depends on the use of this drug. Progress has been made on understanding 
the mechanisms causing the toxicity and some of the predisposing factors. Expert 
counselling and management of the hearing loss, tinnitus and or vertigo is very 
important for all children. Understanding and adaptation at home, school and in 
the work place can facilitate better integration and outcomes for people suffering 
from acquired toxicity. Otoprotective drugs are being researched to reduce the 
severity of hearing loss and some will hopefully soon be licenced for use. However 
further research is needed in all areas to improve the quality of life for children who 
acquire this challenging side effect of treatment.
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